The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Impact of TMTV on PFS following glofitamab treatment in R/R DLBCL
Joshua Brody, MD, The Tisch Cancer Institute Mount Sinai, New York, NY, discusses a follow-up from a Phase II trial (NCT03075696) investigating outcomes of glofitamab treatment in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) dependent on total metabolic tumor volume (TMTV). The findings reveal significantly worse outcomes for patients above the median TMTV, with a 12-month progression-free survival (PFS) of 15% compared to 50% in patients with a lower-than-average TMTV. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: SeaGen, Merck, BMS, Pharmacyclics, ADC Therapeutics, Epizyme, Genentech, Inc., Kite
Consultancy: SeaGen, Merck, BMS, Pharmacyclics, ADC Therapeutics, Epizyme, Genentech, Inc., Kite
